SelvitaWAR:SLV +3.27%81 Net Margin % is -7.19% as of Mar. 2026. GuruFocus rates WAR:SLV with a GF Score™ of 81/100 and a GF Value™ of zł58.46 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Selvita ranks better than 52.45% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Selvita's Net Income for the
three
months ended in Mar. 2026 was zł-5.4 Mil. Selvita's Revenue for the
three
months ended in Mar. 2026 was zł75.8 Mil. Therefore, Selvita's net margin for the quarter that ended in Mar. 2026 was -7.19%.
The historical rank and industry rank for Selvita's Net Margin % or its related term are showing as below:
WAR:SLV'
s Net Margin % Range Over the Past 10 Years
Min: -1.78 Med: 7.19 Max: 20.15
Current: -1.04
WAR:SLV's Net Margin % is ranked better than 52.45% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.405
vs WAR:SLV: -1.04
Selvita (WAR:SLV) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Selvita Net Margin % Related Terms
Selvita Net Margin % Historical Data
* Premium members only.
The historical data trend for Selvita's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:SLV vs TMO, DHR, IDXX: Net Margin % Comparison
For the Diagnostics & Research subindustry, Selvita's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Selvita Net Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Selvita's Net Margin % distribution charts can be found below:
* The bar in red indicates where Selvita's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Selvita (WAR:SLV) has a Net Margin % of -7.19% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Selvita and its competitors. According to the industry distribution chart, Selvita ranks #97 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 47.5%.
Is Selvita's Net Margin % too high?
Selvita's current Net Margin % is -7.19%. Based on the distribution chart, Selvita ranks #97 out of 204 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Selvita has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Selvita's Net Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Selvita ranks #97 out of 204 companies for Net Margin %. This puts Selvita in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Selvita and its competitors. Selvita's current Net Margin % is -7.19%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Selvita stock overvalued right now?
Based on GuruFocus' analysis, Selvita (WAR:SLV) is currently considered Significantly Undervalued. The stock's GF Value™ is zł58.46, compared to a current price of zł31.60 — trading 45.9% below its estimated fair value. The current Net Margin % is -7.19%. Selvita's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Selvita (WAR:SLV), the current Net Margin % is -7.19% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Selvita (WAR:SLV) Overvalued in 2026?
Based on GuruFocus' analysis, Selvita stock appears to be undervalued.
The current stock price of zł31.60 is trading 45.9% below its estimated GF Value™ of zł58.46.
GuruFocus considers Selvita to be Significantly Undervalued.
Key valuation signals for WAR:SLV:
Net Margin %: -7.19%
GF Value™: zł58.46 vs. price of zł31.60 (45.9% below fair value)
No single metric tells the full story. See the WAR:SLV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Selvita SA is a Poland based parent company of Selvita Group is one of the largest preclinical contract research organizations in Europe. It also develops bioinformatics solutions supporting innovative projects at preclinical stages. It also provides services provided to external contractors are in the field of chemistry, analytics, regulatory, biochemistry and cell biology and also the integrated research and development projects.
81GF Score
Get the complete analysis for WAR:SLV
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SLV has been successfully added to your 
